Would you use apalutamide in high risk non-metastatic castrate resistant prostate cancer?
The recent SPARTAN trial showed a remarkable improvement in metastasis free survival and many other secondary endpoints except the lack of significant benefit in OS, which may be related to the immaturity of the data at this time.
Community PollStarted
Would you use apalutamide in high risk non-metastatic castrate resistant prostate cancer?
38 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · University of Virginia
Answered on
I would consider using apalutamide for the appropriate patient, which I would define as meeting the entry criteria for the study i.e. PSA DT 10 months or less. The label for the drug is broad i.e. any castration resistant PSA only patient, which I beleive is too far to inclusive, many of these folks...
Join for free or sign in to see the full answer